Written Question·Department of Health and Social Care·UIN 74036
Obesity: Drugs
Tabled: 1 September 2025
Answered: 15 September 2025
Question
David Smith
Labour — North Northumberland
To ask the Secretary of State for Health and Social Care, whether he has considered including lipedema as a relevant condition for NHS prescription of (a) Mounjaro injections and (b) other weight loss treatments.
Answer
Dr Zubir AhmedSemaglutide, brand name Wegovy, tirzepatide, brand name Mounjaro, and liraglutide, brand name Saxenda, are approved for the management of obesity. They are recommended as cost-effective for use on the National Health Service for people who have a body mas...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 74036) →